Thermo Fisher Scientific Inc. (NYSE: TMO) has entered a definitive agreement to acquire Brammer Bio, a contract manufacturing organization (CMO) specializing in cell and gene therapies (CGT). Valued at approximately $1.7 billion in cash, the transaction represents one of the most lucrative acquisitions of a cell and gene therapy CMO to date. [Read more…]
Cellectis Secures 82,000 Sq Ft Manufacturing Facility in Raleigh to Compliment Paris Facility
Cellectis, a leading French biopharmaceutic company, has signed a lease agreement for an 82,000 sq. ft. manufacturing facility in Raleigh, North Carolina, to complement its existing 14,000 sq. ft. manufacturing facility in Paris, France.
Located at 2500 – 2540 Sumner Boulevard in Raleigh, NC, the new USA facility is owned by Equus Capital Partners and will be used for clinical and commercial production of Cellectis’ leading allogeneic UCART products.
Importantly, the decision will combine the capabilities of Cellectis’ two facilities to advance its manufacturing processes and prepare for potential commercialization of its UCART products in the future. [Read more…]
Gilead Gets Notice of Compliance for Yescarta™ from Health Canada
Yescarta™ is positioned to join Kymriah™ as the second chimeric antigen receptor T cell (CAR-T) therapy to achieve regulatory approval in Canada, based on exciting news released this month from Gilead Sciences Canada. [Read more…]
Webinar Case Study: ‘Companion Informatics’ to Automate Immunotherapy Manufacturing and Treatment
L7 Informatics is honored to host a Free Webinar exploring a Case Study related to “‘Companion Informatics’ to Automate Immunotherapy Manufacturing and Treatment.”
Webinar: Companion Informatics’ to Automate Immunotherapy Manufacturing & Treatment
Genomics-driven precision medicine and regenerative medicine including cell and gene therapies require a new category of “companion informatics” software that automates and synchronizes complex data and process management. This software is applicable throughout the life-cycle of these complex therapeutics as they make their way from bench to clinical trials to bedside. [Read more…]
Sana Biotechnology, Former Juno Therapeutics Execs Co-Found New Biotech
On January 4, 2019, Sana Biotechnology became the latest regenerative medicine company to enter the marketplace, founded by former Juno Therapeutics executives Hans Bishop and Steve Harr, among other all-star executives. With operations in Seattle, WA, Cambridge, MA and San Francisco, CA, the company will be focused on creating engineered cells as medicines for patients.
Based on preliminary company statements, Sana seems to be interested in reproducing the business model and the financial success that characterized Juno Therapeutics – specifically, its ability to attract top talent from across the marketplace, accumulate investor funds, and exit for a major windfall. [Read more…]
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 62
- Next Page »